Media & Press Releases

Inhibition of Ca2+ entry by capsazepine analog CIDD-99 prevents oral squamous carcinoma cell proliferation

Inhibition of Ca2+ entry by capsazepine analog CIDD-99 pr...

Oral cancer patients have a poor prognosis, with approximately 66% of patients surviving 5-years ...

November 05, 2025

View Details
The Novel Capsazepine Analog, CIDD-99, Significantly Inhibits Oral Squamous Cell Carcinoma In Vivo Through a TRPV1-Independent Induction of ER Stress, Mitochondrial Dysfunction, and Apoptosis

The Novel Capsazepine Analog, CIDD-99, Significantly Inhi...

Oral squamous cell carcinoma (OSCC) is a deadly disease with a mere 40% five-year survival rate f...

November 05, 2025

View Details

Awards:

Award Logo Award Logo Award Logo Award Logo Award Logo

Connect

Email cara@keraceuticals.net

Contact Us